MSN Laboratories

MSN Laboratories is one of the fastest-growing, research based, and fully integrated pharmaceutical companies worldwide, with its headquarters in Hyderabad, India. Founded by CMD Dr. MSN Reddy in 2003, MSN Labs' mission has been to make high-quality medicines affordable and accessible worldwide.

The organization currently boasts 25 state-of-the-art manufacturing facilities (17 for API and 8 for finished dosages) alongside Asia’s Largest Integrated R&D Centre, spanning across India and the USA. 

The group’s integrated R&D Centre enables research in both API and Finished Dosages under one roof, empowering the organization to swiftly introduce new and cost-effective therapies in global markets. Supported by a dedicated team of over 20,000 experienced professionals, the organization has gained global recognition for its innovation, quality, and swift delivery.

MSN Labs maintains robust regulatory protocols and streamlined approval processes, ensuring that our pharmaceutical products meet international benchmarks. This has positioned us as a trusted global provider of pharmaceuticals, earning accreditations from reputable organizations such as USFDA, WHO, KSFDA, EDQM, PMDA Japan, and Health Canada. Our commitment to enhancing the regulatory framework promises that the medicines manufactured at our state-of-the-art facilities meet the highest standards of safety, efficacy, and quality.

MSN Group highlights: 

• 25 Manufacturing units (including one in USA)
• 20000 employees globally and presence in over 100 countries 
• World no. 1 in active US DMF filings, one stop solution – End to end integration 
• Having one of Asia’s largest R&D center with over 2000 scientists 
• Revenue of over 1 Billion $
• Manufacturing capacities: Small to Large batch size for API and Formulations – This enables flexibility for our customers 
• World class manufacturing facilities with global accreditations 
• Online Project management systems – Transparent and Realtime communications 

Regulatory Achievements and Accreditations

• Filed over 1200 total number of Drug master files globally
• Filed over 170 Abbreviated New Drug Applications in USA and over 3000-finished product Dossiers worldwide.
• ISO 9001:2000 certification (< 20 months of inception) and ISO 45001 for Health and safety, ISO 14001 for environmental management system
• WHO:GMP approval (< 24 months of inception)
• EU:GMP approval (< 48 months of inception)
• USFDA approval (< 52 months of inception) 
• Department of Science & Technology, Govt. of India.
• Department of Scientific and Industrial Research, Govt. of India
• Hamburg Authorities, Germany.
• Korean FDA approval.
• WHO Geneva inspection
• PMDA – Japan

Sustainable future

As a global company, we hold a substantial responsibility and a great opportunity to assume a leadership role in promoting and advancing Environmental, Social, and Governance (ESG) standards. We recognize the importance of prioritizing positive & sustainable impact as a fundamental objective within our business operations.

Our journey towards sustainability starts with a commitment to reduce wastage and recycle. We invest in innovative technologies and processes that promote energy efficiency, reduce greenhouse gas emissions, and minimize waste generation. From our manufacturing facilities to our supply chain, we strive for sustainability and hold ourselves accountable for achieving measurable targets.

But sustainability is not just about the environment, it is about people too. We recognize the importance of fostering a diverse, inclusive, and equitable workplace. We work tirelessly to create an environment where every individual feels valued, respected, and empowered to reach their full potential.